Stemtech Corporation Now Ranked 11th in Momentum Out of Over 700 Global MLM Companies

Rhea-AI Summary

Stemtech Corporation (OTCQB: STEK) has achieved a remarkable rise in its ranking, moving from 159th to 11th in the Business For Home 'Momentum' category, demonstrating significant growth in the network marketing industry. This leap validates Stemtech's strategic efforts, including the launch of their Stemtech AdvanceOffice mobile app and the introduction of the CellectOne™ Rapid Renew Stem Cell Peptide Night Cream. CEO Charles S. Arnold emphasized that this achievement reflects the company's ongoing upward trend, supported by its Independent Business Partners' enthusiasm and new product development initiatives set forth in their VISION 2023 strategy.

Positive

• Ranked 11th in Momentum by Business For Home, up from 159th, indicating strong growth.
• Introduction of innovative products like CellectOne™ and the AdvanceOffice mobile app, enhancing market presence.
• Successful execution of VISION 2023 strategy, fostering engagement among Independent Business Partners.

Negative

• None.

Moving up from 159th to 11th in ranking Substantiates our Aggressive growth and Market Presence

MIRAMAR, FL / ACCESSWIRE / January 23, 2023 / Stemtech Corporation (OTCQB:STEK) today announced Soaring Momentum as published by independent network marketing industry publication "Business For Home".

President and Chief Operating Officer, John W. Meyer, says "Stemtech is now ranked number 11 in Momentum by ‘Business For Home' out of over 700 top (there are thousands) global network marketing companies as determined by 'Business For Home'. We are proud of this accomplishment, as it independently substantiates our growth and progress. On April 28, 2022, we were ranked number 159 as noted in our press release. On June 28, 2022, we advanced to number 93 per our press release. Today, we excelled and are ranked number 11. This significant rise in status validates our market presence and growth".

(https://www.businessforhome.org/companies/stemtech/)

Mr. Meyer goes on to say "with our ‘VISION 2023' strategy, announced January 18th, 2023, we are executing on the foundation established in 2022 with new marketing, the introduction of our powerful Stemtech AdvanceOffice mobile app, the introduction of newly branded Stemtech CellectOne™ proprietary blend Rapid Renew Stem Cell Peptide Night Cream, and our Leadership Conference last December in Cancun, Mexico. Our Independent Business Partners (IBPs) were thrilled with the event and continue to demonstrate their enthusiasm with unwavering passion for sharing Stemtech. In addition, Stemtech is planning to introduce new disruptive products being designed by Life Factor Research, a Division of Stemtech Corporation".

Stemtech CEO, Charles S. Arnold, says "as we demonstrate execution of our strategy, including the income earning opportunity business aspect of our IBPs and customers, growth continues on the upward trend. The 'Business For Home' rank advancements, based upon twelve measured categories used to track status, shows that Stemtech continues to be recognized as an industry leader".

ABOUT STEMTECH

Stemtech Corporation, a leading stemceutical™ company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, Inc., which was established in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, Stemtech underwent an extensive executive reorganization, and continued operations under new leadership as Stemtech Corporation. In August 2021, Stemtech became a publicly traded company (OTCQB: STEK) and has expanded business opportunities for its Independent Business Partners, who may earn incomes by sharing Stemtech products. January 2022 saw the introduction of new marketing efforts. In August 2022, Professor Doctor Bankole Johnson joined Dr. Enrique Martinez and Dr. Lizette Leos on the Stemtech Life Sciences Advisory Board. In September 2022, the new Stemtech AdvanceOffice mobile app based on the VERB Technology platform was successfully launched as a powerful communication - recruiting tool for our Field. In October, Life Factor Research became the Research and Development, product formulation - science division of Stemtech to create cutting-edge stemceuticals and other products. On November 1, 2022, Stemtech introduced the new travel/sample size OraStem® Toothpaste. On December 6, Stemtech announced the promotion of Alejandro Carrillo to the role of Vice President Global Sales from his current role as Managing Director Latin Markets. Stemtech introduced the new CellectOne™ Rapid Renew Stem Cell Peptide Night Cream at their December 2022 International Leadership Event in Cancun, Mexico. January 10 2023 Stemtech appoints Margie and Mike Mares to Field Advisory Board.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on November 23, 2022. We undertake no duty to update any forward-looking statement, or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.

www.Stemtech.com

Investor Relations:
Phone: 954-715-6000 ext 1040
Email: invrel@stemtech.com

SOURCE: Stemtech Corporation

View source version on accesswire.com:
https://www.accesswire.com/736218/Stemtech-CorporationNow-Ranked-11th-in-Momentum-Out-of-Over700-Global-MLM-Companies

FAQ

What significant ranking change did Stemtech Corporation achieve recently?

Stemtech Corporation moved from 159th to 11th in the Momentum ranking by Business For Home.

How does Stemtech's new mobile app contribute to its growth?

The Stemtech AdvanceOffice mobile app serves as a powerful communication and recruiting tool for Independent Business Partners.

What is the significance of Stemtech's VISION 2023 strategy?

VISION 2023 outlines new marketing initiatives and product launches aimed at enhancing the company's growth and market engagement.

What products has Stemtech introduced to boost its market presence?

Stemtech has introduced the CellectOne™ Rapid Renew Stem Cell Peptide Night Cream and the AdvanceOffice mobile app.

How does Stemtech's ranking affect investors?

The significant improvement in ranking indicates strong growth and market presence, which may positively influence investor sentiment.